Biogen Idec and Neurimmune Therapeutics AG entered an agreement for the worldwide development and commercialization of fully human antibodies for the treatment of Alzheimer’s disease (AD). The alliance will focus on the development of antibodies that bind to amyloid beta (Aβ), a pathogenic molecule thought to cause neurodegeneration and loss of cognitive function in AD patients. Currently there are no therapies for AD approved to slow or stop disease progression. Neurimmune will conduct re...